CytoSorbents STAR-T trial misses primary effectiveness endpoint in overall population; positive trend in CABG subgroup

Cytosorbents Corp

STAR-T trial did not meet primary composite effectiveness endpoint in overall 140-patient population.
Safety endpoint met; DSMB found no safety issues with DrugSorb-ATR device.
In isolated CABG subgroup (over 90% of patients), reduced bleeding complications observed, including serious events.
Company expects to complete full data analysis in weeks and may submit to FDA/Health Canada.
Full results to be presented at ACC 2024 in Atlanta next April if accepted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.